To include your compound in the COVID-19 Resource Center, submit it here.

AMPK addendum

Merck sees cardiovascular toxicity in animal studies of pan-AMPK agonist

A Science paper form Merck & Co. Inc. (NYSE:MRK) suggests that while AMP-activated protein kinase (AMPK) agonists can reduce blood sugar levels and treat diabetes models, they also cause cardiac defects, casting doubt on AMPK agonists in clinical testing for the indication.

The AMPK pathway is a primary regulator of energy level responses in cells, with activated AMPK phosphorylating downstream proteins to modulate

Read the full 628 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE